Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. Roos I, et al. JAMA Neurol. 2023 Aug 1;80(8):789-797. doi: 10.1001/jamaneurol.2023.1625. JAMA Neurol. 2023. PMID: 37307006 Free PMC article.
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.
Neller MA, Ambalathingal GR, Hamad N, Sasadeusz J, Pearson R, Holmes-Liew CL, Singhal D, Tunbridge M, Ng WY, Sharplin K, Moore A, Deambrosis D, Soosay-Raj T, McNaughton P, Whyte M, Fraser C, Grigg A, Kliman D, Bajel A, Cummins K, Dowling M, Yeoh ZH, Harrison SJ, Khot A, Tan S, Roos I, Koo RM, Dohrmann S, Ritchie D, Wainstein B, McCleary K, Nelson A, Gardiner B, Inam S, Badoux X, Ma K, Toro C, Hanna D, Hughes D, Conyers R, Cole T, Wang SS, Chee L, Fleming J, Irish A, Purtill D, Cooney J, Shaw P, Tey SK, Hunt S, Subramonia Pillai E, John G, Ng M, Ramachandran S, Hopkins P, Chambers D, Campbell S, Francis R, Isbel N, Marlton P, Reddiex H, Matthews KK, Voogt M, Panikkar A, Beagley L, Rehan S, Best S, Raju J, Le Texier L, Crooks P, Solomon M, Lekieffre L, Srihari S, Smith C, Khanna R. Neller MA, et al. Among authors: roos i. Nat Commun. 2024 Dec 3;15(1):10339. doi: 10.1038/s41467-024-54595-2. Nat Commun. 2024. PMID: 39627190 Free PMC article.
Early clinical markers of aggressive multiple sclerosis.
Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Eichau S, Bergamaschi R, Sola P, Ferraro D, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Grand'Maison F, Ozakbas S, Van Pesch V, Granella F, Hupperts R, Pucci E, Boz C, Sidhom Y, Gouider R, Spitaleri D, Soysal A, Petersen T, Verheul F, Karabudak R, Turkoglu R, Ramo-Tello C, Terzi M, Cristiano E, Slee M, McCombe P, Macdonell R, Fragoso Y, Olascoaga J, Altintas A, Olsson T, Butzkueven H, Hillert J, Kalincik T. Malpas CB, et al. Among authors: roos i. Brain. 2020 May 1;143(5):1400-1413. doi: 10.1093/brain/awaa081. Brain. 2020. PMID: 32386427 Free article.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepany T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators. Roos I, et al. Brain. 2020 Sep 1;143(9):2742-2756. doi: 10.1093/brain/awaa231. Brain. 2020. PMID: 32947619 Free article.
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.
Seery N, Li V, Nguyen AL, Roos I, Buzzard KA, Atvars R, Taylor N, Tunnell K, Carey J, Dwyer C, Taylor HFL, Baker J, Marriott MP, Kilpatrick TJ, Kalincik T, Monif M. Seery N, et al. Among authors: roos i. Mult Scler Relat Disord. 2020 Nov;46:102516. doi: 10.1016/j.msard.2020.102516. Epub 2020 Sep 16. Mult Scler Relat Disord. 2020. PMID: 32957057 Free PMC article.
Determinants of therapeutic lag in multiple sclerosis.
Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Debouverie M, Trojano M, Patti F, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grammond P, Ciron J, Ruet A, Ozakbas S, De Seze J, Louapre C, Zephir H, Sá MJ, Sola P, Ferraro D, Labauge P, Defer G, Bergamaschi R, Lebrun-Frenay C, Boz C, Cartechini E, Moreau T, Laplaud D, Lechner-Scott J, Grand'Maison F, Gerlach O, Terzi M, Granella F, Alroughani R, Iuliano G, Van Pesch V, Van Wijmeersch B, Spitaleri D, Soysal A, Berger E, Prevost J, Aguera-Morales E, McCombe P, Castillo Triviño T, Clavelou P, Pelletier J, Turkoglu R, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Sidhom Y, Gouider R, Csepany T, Bourre B, Al Khedr A, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanche JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Coles A, Malpas CB, Vukusic S, Butzkueven H, Kalincik T. Roos I, et al. Mult Scler. 2021 Oct;27(12):1838-1851. doi: 10.1177/1352458520981300. Epub 2021 Jan 11. Mult Scler. 2021. PMID: 33423618 Free article.
86 results